Ponatinib for chronic phase CML
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how the drug ponatinib works in people with chronic phase CML. It aims to understand how the body handles the drug and if it helps control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have chronic phase CML.
- You have been taking ponatinib at 15, 30, or 45 mg each day for at least 14 days.
- You agree to take part in the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies ponatinib as a second treatment for chronic myeloid leukemia (CML) when it didn’t fully respond or couldn’t be tolerated with at least one prior CML pill. It aims to see whether ponatinib can better control leukemia levels after earlier treatments.
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
This study looks at how well ponatinib works for adults with a specific type of acute lymphoblastic leukemia (Ph+ ALL) when used as a first treatment, either alone or with other therapies. It aims to help doctors understand the real-world benefits and outcomes of this treatment.
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
Hear when a new Chronic Myeloid Leukemia, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.